HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab-Reference-Cited by-同舟云学术

HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab

Published:2002-11 Issue:11 Volume:93 Page:1250-1257
ISSN:0910-5050
Container-title:Japanese Journal of Cancer Research
language:en
Short-container-title:

Author:

Fujimura Masaki,Katsumata Noriyuki,Tsuda Hiroshi,Uchi Naoko,Miyazaki Satomi,Hidaka Takao,Sakai Masatoshi,Saito Shigeru

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2002.tb01231.x/fullpdf

Reference48 articles.

1. Endometrioid and clear cell carcinoma of the ovary. Factors affecting survival;Brescia;Int. J. Gynecol. Pathol.,1987

2. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma;Jenison;Gynecol. Oncol.,1989

3. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary;Kita;Oncol. Rep.,2000

4. Prognosis of Japanese patients with ovarian clear cell carcinoma associated with pelvic endometriosis: clinicopathologic evaluation;Komiyama;Gynecol. Oncol.,1999

5. Absence of estrogen receptor-α expression in human ovarian clear cell adenocarcinoma compared with ovarian serous and endometrioid adenocarcinoma;Fujimura;Am. J. Surg. Pathol.,2001

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors;npj Precision Oncology;2024-09-12

2. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2;Clinical & Experimental Metastasis;2024-06-22

3. Exceptional Response to Trastuzumab Deruxtecan in a Patient With Recurrent Ovarian Clear Cell Carcinoma With Human Epidermal Growth Factor Receptor 2 Expression;JCO Precision Oncology;2024-06

4. Genetic Links between Endometriosis and Endometriosis-Associated Ovarian Cancer—A Narrative Review (Endometriosis-Associated Cancer);Life;2024-05-30

5. Human Epidermal Growth Factor Receptor 2 Overexpression/Amplification in Primary Ovarian Endometrioid Carcinoma;Applied Immunohistochemistry & Molecular Morphology;2024-04-18